FDA Raises Concerns About Patanase Inactive Ingredient
This article was originally published in The Pink Sheet Daily
Executive Summary
Alcon is testing a modified formulation of the olopatadine nasal spray, which is awaiting approval for treatment of seasonal allergic rhinitis.